Fresenius Kabi has launched Neostigmine Methylsulfate Injection in the Simplist ready-to-administer syringe. The single-dose prefilled syringe is supplied in a 3mg/3mL dosage strength and is the first manufacturer-prepared formulation of this product on the market.
Neostigmine Methylsulfate is a cholinesterase inhibitor indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents after surgery. Fresenius Kabi gained approval for Neostigmine Methylsulfate, the generic version of Bloxiverz, in 2015.
Neostigmine Methylsulfate Injection, USP Simplist is supplied in packs that include 10 syringes. The Company also continues to manufacture Neostigmine Methylsulfate Injection in 5mg/10mL and 10mg/10mL multi-dose vials.
“This is the fourth Simplist product we’ve introduced this year and represents the strength of our pipeline of important therapies and delivery systems that can help physicians practice more efficiently,” said John Ducker, president and CEO of Fresenius Kabi USA.
For more information visit Fresenius-Kabi.us.
This article originally appeared on MPR